|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||92.08 - 96.71|
|52 Week Range||36.15 - 151.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]
The European Medical Agency (EMA) is reportedly set to recommend Johnson & Johnson’s (NYSE: JNJ) coronavirus vaccine on March 11, according to Bloomberg. The European Commission said deliveries of the J&J shot are expected to begin in early April, thus bolstering the supplies over the second and third quarters. The EU inked a purchase deal with JNJ to supply doses for 200 million people, with an option for an additional 200 million. The EU official also said that the agency is in talks with Russian authorities on the Sputnik V vaccine and may receive data soon to begin a rolling review process. The EMA is also carrying out a rolling review of the CureVac BV (NASDAQ: CVAC) and Novavax Inc (NASDAQ: NVAX) shots. The European Commission has agreed to purchase 225 million CureVac shots and 100 million doses from Novavax. On Wednesday, the FDA backed the JNJ’s single-shot COVID-19 vaccine, which protected from the infection after receiving the vaccine. The FDA Adcom meeting to review JNJ’s shot is scheduled today. Price Action: JNJ shares are up by 0.28% at $163.21, NVAX shares are down 1.4% at $218.4, and CVAC shares are up 1.5% at $94.36 in the premarket session on the last check Friday. See more from BenzingaClick here for options trades from BenzingaModerna Raises 2021 Base COVID-19 Vaccine Production Plan To 700M DosesModerna To Test New COVID-19 Vaccine Targeting South Africa Strain© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
You might have thought the coronavirus vaccine race ended when Pfizer (NYSE: PFE) crossed the finish line first in December. Variants from Brazil, the U.K., and South Africa worry the scientific community (and the rest of us) the most at the moment. Johnson & Johnson (NYSE: JNJ) highlighted exactly how its investigational vaccine performed against those new strains in its phase 3 trial.